Opsidio Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
4
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$422M
Opsidio General Information
Description
Developer of monoclonal antibodies designed to treat patients suffering from fibrotic and allergic diseases. The company's antibodies target the unique form of the stem cell factor that drives the cascade of profibrotic cytokines, enabling doctors to treat fibrotic and remodeling diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma.
Contact Information
Website
www.opsidio.comCorporate Office
- PO Box 802
- Bryn Mawr, PA 19010
- United States
Corporate Office
- PO Box 802
- Bryn Mawr, PA 19010
- United States
Opsidio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 01-Dec-2025 | $422M | Completed | Generating Revenue | ||
| 3. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 2. Later Stage VC | 31-Jan-2018 | $1.72M | $1.72M | Completed | Generating Revenue | |
| 1. Grant | 01-Jan-2017 | $217K | Completed | Generating Revenue |
Opsidio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Opsidio Patents
Opsidio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3212098-A1 | Stem cell factor antibodies and methods of use thereof | Pending | 17-Mar-2021 | ||
| WO-2022197914-A2 | Stem cell factor antibodies and methods of use thereof | Inactive | 17-Mar-2021 | ||
| WO-2022197914-A3 | Stem cell factor antibodies and methods of use thereof | Inactive | 17-Mar-2021 | ||
| CA-3154648-A1 | Anti-stem cell factor antibodies and methods of use thereof | Pending | 16-Sep-2019 | ||
| ES-3053942-T3 | Anti-stem cell factor antibodies and methods of use thereof | Active | 16-Sep-2019 | C07K16/24 |
Opsidio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Opsidio Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioAdvance Capital (Conshohocken) | Venture Capital | Minority | ||
| Innovation Partnerships | Venture Capital | Minority | ||
| Mid Atlantic Bio Angels | Angel Group | Minority | ||
| National Institute of Diabetes and Digestive and Kidney Diseases | Government |
Opsidio FAQs
-
When was Opsidio founded?
Opsidio was founded in 2012.
-
Where is Opsidio headquartered?
Opsidio is headquartered in Bryn Mawr, PA.
-
What is the size of Opsidio?
Opsidio has 4 total employees.
-
What industry is Opsidio in?
Opsidio’s primary industry is Drug Discovery.
-
Is Opsidio a private or public company?
Opsidio is a Private company.
-
What is the current valuation of Opsidio?
The current valuation of Opsidio is .
-
What is Opsidio’s current revenue?
The current revenue for Opsidio is .
-
How much funding has Opsidio raised over time?
Opsidio has raised $1.72M.
-
Who are Opsidio’s investors?
BioAdvance Capital (Conshohocken), Innovation Partnerships, Mid Atlantic Bio Angels, and National Institute of Diabetes and Digestive and Kidney Diseases have invested in Opsidio.
-
When was Opsidio acquired?
Opsidio was acquired on 01-Dec-2025.
-
Who acquired Opsidio?
Opsidio was acquired by Insmed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
